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Abstract
Interferons (IFNs) suppress cell growth by inducing cellular genes. The anti-estrogen tamoxifen (Tam), binds to estrogen
receptor and inhibits transcription of estrogen stimulated genes. In cells resistant to IFN-induced growth suppression, IFN/
Tam combination causes cell death. We previously reported that the combination of IFN-L and Tam was a more potent
growth suppressor of human tumor xenografts than either agent alone. The IFN/Tam combination acts in a manner similar
to the IFN/retinoic acid combination. Using a genetic technique, we have recently identified several genes associated with
retinoid-IFN-induced mortality (GRIM). One such gene, GRIM-12, was identical to human thioredoxin reductase (TR). In
the present study we have examined whether the IFN/Tam combination also requires GRIM-12 for inducing cell death. We
report here that GRIM-12 is necessary for mediating the cell death effects of IFN/Tam, and its expression is induced by IFN/
Tam at a post-transcriptional stage. Repression of GRIM-12 levels either by antisense expression or by dominant negative
inhibitors caused resistance to IFN/Tam induced death and promoted cell growth. Overexpression of GRIM-12 increased
IFN/Tam induced apoptosis. Thus, these studies have identified a critical role for GRIM-12 (TR) in apoptosis. ß 2000
Elsevier Science B.V. All rights reserved.
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1. Introduction
Interferons (IFNs) are a family of cytokines which
exhibit antitumor activity [1]. Employing the Janus
tyrosine kinase (JAK)-signal transducing activator of
transcription (STAT) proteins [2], they induce a
number of cellular IFN-stimulated genes (ISG) that
mediate their biological actions. Although the anti-
viral actions of IFNs have been relatively well appre-
ciated [3], their antitumor actions are poorly under-
stood. Approximately 250 genes are induced and
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10 others are repressed in IFN-treated cells. IFN-K
activates growth suppressor proteins such as pRb
[4,5] and downregulates growth promoters such as
c-myc in the Daudi lymphoma cell line [6]. In addi-
tion, certain members of the IFN-gene regulatory
factor (IRF) family act as tumor suppressor genes
by activating apoptosis. Gene mutations or dysregu-
lation of IRF-1 and ICSBP (IFN-consensus sequence
binding protein) have been described in human mye-
loid leukemias [7^10]. Since these molecules are IFN-
regulated transcription factors, their activities are de-
pendent on either the induction of growth inhibitory
gene products or the suppression of growth promot-
ing factors [9]. Other studies suggest that protein ki-
nase R (PKR) and ribonuclease L (RNaseL), which
inhibit viral growth in IFN-treated cells [11,12], also
suppress cell growth in response to IFN [13,14].
Tamoxifen (Tam), an estrogen antagonist, inhibits
cell growth by blocking the activity of estrogens [15].
Estradiol stimulates cell growth, probably by activat-
ing certain genes whose promoters bind the ligand-
engaged estrogen receptor (ER). Tam is thought to
suppress estradiol inducible genes by a competitive
inhibition of estradiol binding to ER [15,16]. In ad-
dition to estrogen responsive tumors, Tam also in-
hibits growth of other estrogen independent tumors
in the xenograft model and in culture [17^21]. There-
fore, in addition to inhibition of ER function, Tam
exerts anticellular e¡ects via other unde¢ned mecha-
nisms.
Despite their potent therapeutic activity in leuke-
mias, IFNs have less activity against most solid tu-
mors [22]. Several studies have shown that the com-
bination of IFNs and Tam exhibits a signi¢cant
tumor suppressive e¡ect [23^27]. We have observed
that the combination of human IFN-L with Tam
synergistically suppresses the growth of transplanted
human breast and ovarian tumor xenografts in athy-
mic nude mice [28]. Further, the IFN/Tam combina-
tion causes cell death in vitro [29], similar to the
combination of IFN-L and all trans retinoic acid
(RA). Using a genetic technique, we have recently
identi¢ed several genes that mediate cell death e¡ects
of the IFN/Tam combination. [30]. These analyses
revealed that thioredoxin reductase (TR), an intra-
cellular redox regulatory enzyme [31], is essential for
mediating cell death. In this study, using a combina-
tion of genetic and biochemical approaches, we show
that TR also participates in induction of cell death
by the IFN/Tam combination.
2. Materials and methods
2.1. Reagents
Restriction and DNA modifying enzymes (NE
Biolabs); azelaic acid (AZ), DTT, PMSF, Triton-X,
Tam (Sigma); G418 Sulfate (Life Technologies); ni-
trocellulose membranes, ECL reagents and horserad-
ish peroxidase coupled to anti-rabbit antibodies
(Amersham); human IFN-L1b (Berlex); human
IFN-K2b (Ho¡mann La Roche); human IFN-Q
(Boehringer Mannheim); hygromycin B (Boehringer
Mannheim); anti-actin antibodies (Santa Cruz Bio-
tech); monoclonal anti-eIF-2K antibodies [32], anti
PKR antibodies [33] and anti RNaseL antibodies
[34] were employed in this study. Fresh stocks of
Tam were prepared in ethanol.
2.2. Cell culture
All estrogen dependent cells were cultured in phe-
nol red free EMEM supplemented with 5% charcoal
stripped fetal bovine serum (CSFBS) and 10311 M
estradiol during treatment with IFN-L and Tam.
Cells were grown in phenol red free media 24 h be-
fore treatments were initiated. All other cell lines
were cultured in media with phenol red but supple-
mented with 5% CSFBS prior to treatment with
IFN-L and Tam.
2.3. Cell growth assays
Cells (2000 cells/well) were treated with various
concentrations of IFN-L and Tam in EMEM with
5% CSFBS in 96-well plates. Growth was quanti-
tated after 5^7 days using a colorimetric assay which
measured cell number [35]. Each treatment group
contained six replicates. Cells were ¢xed with 10%
trichloroacetic acid (TCA) and were stained with
0.4% sulforhodamine B (Sigma) in 1% acetic acid
for 1 h at the end of the growth period. After wash-
ing, bound dye was eluted from cells with 100Wl Tris^
HCl (pH 10.5), and absorbance was measured at
570 nm. A control plate was ¢xed with TCA 8h after
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plating to determine the absorbance representing the
starting cell number. Absorbance obtained with this
plate was de¢ned as 0% growth. Absorbance ob-
tained with untreated cells at the end of the growth
period was de¢ned as 100% growth. When expressed
as a percentage of untreated cells, an increase in cell
number falls on the positive scale and a decrease in
cell number (death) appears on the negative scale.
This method quantitates cell growth with accuracy
comparable to a Coulter counter. To determine cell
cycle distribution, cells collected after various treat-
ments were ¢xed, treated with 500 mg/ml RNaseA,
stained with propidium iodide [36] and analyzed by
FACScan (Becton-Dickinson).
2.4. Northern blot analysis
Total RNA (20 Wg) was separated on 1% formal-
dehyde agarose gels, transferred to nylon membrane,
and probed with 32P-labeled PCR product of the
(gene associated with retinoid-IFN-induced mortal-
ity, GRIM)-12 cDNA. Prehybridization, hybridiza-
tion and washing was carried out under stringent
conditions [37].
2.5. Western blot analysis
Total protein was extracted after various treat-
ments using the freeze/thaw method. Total protein
(50 Wg) was separated on 10% acrylamide gels and
transferred to PVDF membrane (NEN). Membranes
were incubated with primary antibody raised against
the peptide VVGFHVLGPNAGEVTQGFAA, de-
rived from the native enzyme [31]. After stringent
washing, membranes were incubated with anti-rabbit
IgG antibody conjugated to horseradish peroxidase
and developed using ECL reagents (Amersham).
2.6. Enzymatic assay
TR activity was determined as described [38]. Cell
extracts were prepared after IFN/Tam treatment by
freeze-thaw lysis. Extracts (20 Wg) were incubated
with insulin, NADPH and thioredoxin (Trx) in
0.2M HEPES, pH 7.6 for 20 min at 37‡C. Reactions
were stopped with 6 M guanidinium hydrochloride/
0.4 mg/ml dithiobis(2-nitrobenzoic acid) in 0.2 M
Tris, pH 8.0. Absorbance at 412 nm was measured.
In each case a corresponding control without Trx
was used to determine the basal level of TR activity
(due to endogenous Trx and NADPH). Absorbance
values obtained from these controls were subtracted
from those obtained with the reactions that con-
tained Trx and NADPH. A control reaction without
cell extracts but with all other reaction components
was also employed. Triplicate samples were meas-
ured for enzymatic activity. Pure TR was used as a
positive control.
2.7. Protein kinase R and ribonuclease L assays
PKR activity was measured by eIF2K phosphory-
lation [39]. Phosphorylation of eIF-2K was moni-
tored by vertical slab isoelectric focussing, followed
by Western blotting with eIF-2K speci¢c antibodies.
Cell lysates were also analyzed by Western blots for
the presence of PKR protein, eIF2K and actin using
speci¢c antibodies. RNaseL activity was monitored
by cross-linking equal amount of cell extracts with
32P-labeled 2-5A [40], followed by electrophoresis on
10% SDS-PAGE and autoradiography. Levels of
RNaseL protein were measured using monoclonal
antibody against human RNaseL. Activity of these
enzymes in tumor samples was determined as follow-
ing. Athymic nude mice bearing palpable human tu-
mor xenografts (5 mm diameter) were treated with
indicated agents for 8 weeks as described previously
[28]. Tumors from each treatment group were har-
vested and snap frozen in liquid nitrogen. Tumor
protein extracts (50 Wg) were assayed for enzymatic
activity.
3. Results
3.1. IFN-L and Tam synergistically induce death in
human breast and ovarian carcinoma cells
To show that the IFN/Tam combination was tu-
moricidal in vitro, several breast and ovarian carci-
noma cell lines were treated with various IFNs alone
or in combination with Tam. After 1 week, cells were
stained and counted [35]. IFN-L alone caused mini-
mal growth inhibition in MCF-7 (an estrogen re-
sponsive breast carcinoma cell line) in vitro (Fig.
1A). Tam alone (0.5 WM) caused 6 20% growth in-
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hibition. Combination of various doses of IFN-L
with Tam caused a dose dependent growth inhibi-
tion. More importantly, when combined with Tam
(0.5 WM), IFN-L caused cell death at low doses
(150^200 U/ml). Similar results were obtained with
IFN-K (Fig. 1A). However, IFN-L was a more po-
tent inducer of cell death than IFN-K at comparable
doses. In contrast, IFN-Q, when combined with Tam,
synergistically suppressed cell growth but did not
cause cell death (Fig. 1E,F,G,H). To examine
whether cell death also occurred in estrogen inde-
pendent cells, similar studies were performed on
BT-20 cells (Fig. 1B). Tam alone failed to inhibit
BT-20 cell growth. Compared to MCF-7, BT-20 cells
were more sensitive to IFN-L. However, combination
of Tam (0.5 WM) with IFN-L (100 U/ml) caused cell
death. Although the data in the ¢gure depict partial
cell death, total cell death occurred after 9 days (data
not shown). Tam also enhanced growth suppressive
actions of IFN-L in NIH-OVCAR-3 and OCC1 cells.
These cells were more sensitive to IFN-L than Tam,
compared to breast carcinoma cell lines. However,
compared to single agents, treatment with IFN-L/
Tam enhanced the anti-proliferative e¡ects, and re-
sulted in cell death (Fig. 1C,D).
In MCF-7 cells, IFN/Tam caused degradation of
chromosomal DNA without internucleosomal frag-
mentation (data not shown). Therefore, we per-
formed annexin-V-binding assays, which detected
apoptotic cells. IFN/Tam caused a signi¢cant in-
crease in annexin-V positive cells as measured by
£ow cytometry (Fig. 2). However, in NIH-OV-
CAR-3 cells, treatment with IFN-L resulted in inter-
nucleosomal fragmentation of genome in TUNEL
assays and ethidium bromide stained agarose gels
(Fig. 3). Tam enhanced the apoptotic program
when combined with IFN-L but did not induce apop-
tosis as a single agent. We next determined whether
an arrest of cell cycle occurred prior to cell death.
For this purpose cells were treated with various
agents for 5 days, stained with propidium iodide
and analyzed by £ow cytometry. Untreated MCF-7
cells exhibited a normal cell cycle pro¢le (Fig. 4A).
Neither IFN-L (Fig. 4B) nor Tam (Fig. 4C) caused
Fig. 2. Induction of apoptosis in breast carcinoma cells. MCF-7
cells were untreated (None) or treated with IFN-L 200 IU/ml
and 0.5 WM Tam (I-T) for 48 h. Live cells were stained with
annexin-V-FITC and subject to £ow cytometry. Percentage of
cells positive for annexin-V are represented as mean þ S.E.M. of
three samples.
Fig. 1. Antiproliferative and cytotoxic e¡ects of IFNs and Tam.
Human MCF-7 and BT-20 breast carcinoma cells, and NIH-
OVCAR-3 and OCC1 ovarian carcinoma cells were grown in
the presence of human IFNs and Tam (0.5 mM) for 6 days. At
the end of the experiment, cells were ¢xed and stained with sul-
forhodamine B as described in Section 2. Absorbance (570 nm)
of bound dye was quanti¢ed. Growth was expressed as a per-
centage of untreated cells. Each data point was mean þ S.E.M.
of six replicates. A, B, C, D represent experiments done with
IFN-K and IFN-L. E, F, G, H were done with IFN-Q. IFN-K :
a ; Tam+IFN-K : P ; IFN-L : S ; Tam+IFN-L : F ; IFN-Q : 7 ;
Tam+IFN-Q : 8 ; and Tam: b. Values on negative scale indicate
death of initially plated cells.
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cell cycle arrest, consistent with cell growth assays.
Interestingly, the IFN-L/Tam combination did not
cause cell cycle arrest, yet readily induced cell death
(Figs. 2 and 4D). A similar cell cycle pattern was
observed in NIH-OVCAR-3 cells (data not shown).
Thus, in both cell types death occurred independ-
ently of growth arrest.
3.2. IFN/Tam mediated cell death does not involve
PKR and RNaseL
Since cell growth suppression has been attributed
to IFN inducible enzymes, PKR and ribonuclease L
(RNaseL) [13,14], we ¢rst examined whether the
IFN/Tam induced cell death was due to an enhance-
ment of their activity. Cells were treated with drugs
for 5 days and the enzymatic activities of these pro-
teins were determined. RNaseL degrades cellular
RNAs after binding to its activator 2P-5P oligoadeny-
late [12]. RNaseL activity was measured in MCF-7
cells treated in vitro (C) and in tumor xenografts (T)
that regressed in vivo after IFN/Tam therapy. Nei-
ther the physical levels of RNaseL nor its activity
changed with any of the treatments (Fig. 5A,B). Fur-
thermore, no cleavage of ribosomal RNA, a charac-
teristic of RNaseL activation, was observed in these
cells (data not shown).
PKR phosphorylates eukaryotic protein synthesis
initiation factor (eIF-2K), leading to the termination
of polypeptide synthesis and cell growth arrest [11].
No change in the levels of PKR, eIF-2K, and PKR’s
enzymatic activity were detected in MCF-7 cells (Fig.
5C,D,F). Similarly, there was no increase in intra-
tumoral PKR activity in regressing MCF-7 tumor
xenografts harvested from IFN/Tam treated mice.
3.3. GRIM-12 as a mediator of IFN/Tam induced cell
death
Our previous studies utilizing an antisense tech-
nique identi¢ed a number of GRIM genes. GRIM-
12 was identical to the redox regulatory enzyme TR.
We recently showed that antisense GRIM-12 pro-
tects against IFN/RA-induced death [30]. Since we
noted a similarity in the antitumor spectra of the
IFN/Tam and IFN/RA combinations, we asked
whether GRIM-12 mediated the antitumor activity
of IFN/Tam. Cells were transfected with either the
expression vector pTKO1 or pTKO1-GRIM-12,
which expresses GRIM-12 in antisense orientation.
Cells were selected with IFN-L, Tam and hygromy-
cin. The pTKO1 vector has a hygromycin resistance
Fig. 4. Cell cycle analysis of breast carcinoma cells. MCF-7
cells were treated with medium (A), 0.5 WM Tam (B), and 500
U/ml IFN-L (C), or the combination (D), for 5 days. Cells
were ¢xed and stained with propidium iodide after RNaseA
treatment. FACS and cell cycle analyses were performed using
MultiPass software.
Fig. 3. Induction of apoptosis in ovarian carcinoma cells. NIH-
OVCAR-3 cells were left untreated (U) or treated with IFN-L
200 IU/ml (I), 0.5 WM Tam (T), or the combination (IT) for 24
h. Genomic DNA was isolated, treated with RNaseA, separated
on 1% agarose gel and visualized with ethidium bromide; 123-
bp marker (M).
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marker for selection in mammalian cells. Under these
conditions, antisense GRIM-12, but not pTKO1,
protected MCF-7 cells against IFN/Tam-induced
death (Fig. 6). Thus, GRIM-12 appeared to partic-
ipate in IFN/Tam-induced death.
3.4. E¡ect of IFN and Tam combination on the
expression of GRIM-12
To study the e¡ect of IFN/Tam combination on
GRIM-12, we examined whether its mRNA was in-
ducible. Treatment of MCF-7 cells with IFN/Tam
combination did not induce GRIM-12 mRNA sig-
ni¢cantly (Fig. 7A). Reprobing the blots with glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH)
probe con¢rmed the presence of comparable
amounts of RNA in all lanes (data not shown).
Thus, the IFN/Tam combination did not induce the
transcription of GRIM-12.
Therefore, we examined whether the IFN/Tam
combination enhanced GRIM-12 protein levels by
Western blot analysis. The IFN/Tam combination
clearly induced GRIM-12 protein in a time depen-
dent manner (Fig. 7B). We next determined whether
an increase in TR protein correlated with an increase
in enzymatic activity. Insulin reduction assays were
performed to measure TR activity using cell extracts
from IFN/Tam treated cells. Indeed, a higher enzy-
matic activity was detected after 48^72 h IFN/Tam
(Fig. 7C), consistent with Western blot data.
3.5. Antisense mediated inhibition of GRIM-12
expression
Since increased TR activity appeared to mediate
cell death, we determined whether antisense GRIM-
12 inhibited the expression of TR protein. Northern
blot analysis revealed strong expression of antisense
mRNA only in GRIM-12 transfectants (Fig. 8 N).
Western blot analysis indicated that the expression of
antisense GRIM-12 mRNA suppressed TR protein
expression (Fig. 8 W). Using the same extracts we
also determined enzyme activity. Extracts from cells
expressing antisense GRIM-12 had a lower TR ac-
tivity compared to those from control cells (data not
shown). Similar results were obtained with MCF-7
cells (data not shown).
3.6. Overexpression of GRIM-12 mutants inhibits
IFN/Tam-induced cell death
GRIM-12 (TR) is predicted to have a modular
structure [31]. An N-terminal £avin adenine dinu-
Fig. 6. Protection of MCF-7 cells by antisense GRIM-12 epi-
some. Cells were electroporated with indicated episomes (20 Wg)
and selected for 4 weeks with IFN-L (500 U/ml), Tam (0.5 WM)
and hygromycin B (100 Wg/ml). Surviving cells were ¢xed with
TCA (10%) and stained with Giemsa.
Fig. 5. Activation of IFN-stimulated growth inhibitory gene
products does not occur during IFN/Tam induced cell death.
(A) Binding of 32P-2,P5P oligoadenylate to RNaseL. (B) Western
blot analysis of RNaseL. C: Control ; I : IFN-L ; T: Tam; IT:
IFN-L+Tam. a: cultured MCF-7, b: MCF-7 tumor xenograft
in athymic nude mice. The following doses were used: in vitro,
Tam (1 WM) and human IFN-L (500 U/ml) for 5 days; and in
vivo, Tam (66 mg subcutaneous silastic capsule) and human
IFN-L (106 U, subcutaneous) every day for 40 days. Cell or tu-
mor extracts (70 Wg) were assayed for enzymatic activities.
(C^E) Western blot analyses of MCF-7 lysates (50 Wg), using
speci¢c antibodies. (C) anti-PKR; (D) anti-eIF-2K ; and (E)
anti-actin. (F) PKR activity in MCF-7 lysates (50 Wg) as meas-
ured by phosphorylation of eIF-2K. Lanes 1, 2 represent PKR
activity in the untreated and hemin+ dsRNA treated reticulo-
cyte lysates (50 Wg), respectively. After vertical slab gel isoelec-
tric focussing, gels were Western blotted and probed with anti
eIF-2K speci¢c antibodies. Positions of phosphorylated (P) and
unphosphorylated (U) eIF-2K are indicated.
BBAMCR 14611 4-4-00
D.J. Lindner et al. / Biochimica et Biophysica Acta 1496 (2000) 196^206 201
cleotide (FAD) binding domain (FAD domain, or
active domain) and a central NADPH binding do-
main (NBD) and a C-terminal interface domain (ID)
are the major functional domains of this enzyme.
The FAD domain contains cysteine residues essential
for the reduction of its substrate, Trx. The NBD
binds nicotinamide adenine dinucleotide phosphate
dehyrogenase (NADPH), an essential co-factor for
redox enzymes. The ID permits the generation of
functional enzyme via dimerization.
We therefore hypothesized that expression of these
domains would dominantly inhibit the function of
endogenous GRIM-12 (TR). We generated deletion
mutants that contained only one domain using re-
gion speci¢c oligonucleotides and PCR. These inserts
were subcloned into an eukaryotic expression vector,
pCXN2, which also carried a neomycin resistance
gene for selection in mammalian cells. Recombinant
mutants were transfected into MCF-7 cells and sta-
ble cell lines were isolated. Northern blot analyses
revealed the presence of comparable expression of
each mutant domain in the cells (data not shown).
No discernible di¡erences in growth rates of stable
cell lines expressing various mutants were noted
(data not presented).
To test the e¡ect of IFN-L, Tam and their combi-
nation, growth assays were performed using cell lines
that expressed mutant domains of GRIM-12. Treat-
ment with either IFN-L (500 U/ml) or Tam (0.5 WM)
alone caused minimal (6 15%) growth inhibition in
all cells. These observations were consistent with sen-
sitivities of the parental cell line (Fig. 1). However,
treatment with the IFN/Tam combination induced
Fig. 7. E¡ect of IFN-L and Tam on TR expression and activ-
ity. (A) Northern blot analysis of TR using RNA (20 Wg) de-
rived from MCF-7 cells after treatment with IFN-L (500 U/
ml)+Tam (0.5 WM). (B) Western blot analysis of cell extracts
(60 Wg) prepared after IFN-L (500 U/ml) and Tam (0.5 WM)
treatment. Blots were probed with TR speci¢c antibody. (C)
TR activity in IFN/Tam stimulated MCF-7 cell extracts. Cells
were treated as described above. TR activity was determined us-
ing 20 Wg of cell extract from each sample. Each bar represents
mean absorbance þ S.E.M. of triplicate measurements.
Fig. 8. Antisense expression of GRIM-12 interferes with TR ex-
pression. HeLa cells transfected with pTKO1 (P) or GRIM-12
(G) episome were stably selected with hygromycin B for 4 weeks
as described in Section 2. Total RNA (40 Wg) from each cell
line was used for Northern blotting (N). Blots were probed
with 32P-labeled GRIM-12. Antisense (A) and sense (S) GRIM-
12 mRNAs are indicated. Western blotting (W) detected expres-
sion of TR protein in antisense GRIM-12 transfected cells.
Equal amounts of cell extracts (50 Wg) were analyzed. Note the
reduced TR protein expression in the stable antisense GRIM-12
cell line.
Fig. 9. Drug sensitivity of dominant negative mutants. E¡ect of
IFN-L (500 U/ml), Tam (0.5 WM) and their combination on the
growth of MCF-7 cells expressing various domains of GRIM-
12. Growth assays were performed as described in Fig. 1. Each
bar represents mean þ S.E.M. of six replicates in the same ex-
periment. UT: Untransfected cells, FAD: FAD domain, V:
pCXN2 vector.
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cell death in untransfected and vector transfected
cells. Expression of FAD domain did not signi¢-
cantly inhibit the cell growth suppressive e¡ect of
IFN/Tam. NBD conferred slight protection against
IFN/Tam-induced cell death. The ID provided the
strongest protection compared to other domains
(Fig. 9). Remarkably, IFN/Tam combination could
inhibit V65% of cell growth even when the ID was
overexpressed. This was not a clonal e¡ect, because
similar data were obtained for a pooled population
of 100 clones (data not presented).
Since IFN/Tam-induced growth inhibition still oc-
curred in cells expressing ID mutant, it was possible
that the mutant was an ine⁄cient inhibitor due to a
non-native conformation. Therefore, we examined
the e¡ect of AZ, a chemical inhibitor of TR [41],
on IFN/Tam-induced cell death. As expected, IFN/
Tam (IT) caused cell death in MCF-7 cells. Although
AZ caused some growth suppression (14%), it clearly
abrogated IFN/Tam-induced death (Fig. 10). Inter-
estingly, IFN/Tam caused signi¢cant growth inhibi-
tion (78%) even in the presence of AZ. Thus, genetic
and chemical inhibition of TR blocked IFN/Tam-in-
duced death.
3.7. E¡ect of GRIM-12 overexpression on cell growth
Because the above experiments indicated that
blockade of TR function prevented IFN/Tam-in-
duced cell death, the e¡ect of GRIM-12 overexpres-
sion on cell growth was examined. GRIM-12 open
reading frame (ORF) cloned in pCXN2 vector was
electroporated into MCF-7 cells, and G418-resistant
clones were selected. Expression vector alone served
as negative control. Of several identically performed
transfections, one plate was stained with SRB to de-
termine colony counts. Other plates quantitated total
cell number and mRNA expression. Three-fold fewer
colonies formed in the case of GRIM-12-transfected
cells. This result suggested that cells expressing the
highest level of GRIM-12 died during selection. The
surviving drug-resistant colonies from PCXN2 and
GRIM-12 transfected plates were pooled separately,
and their growth was monitored by SRB assay.
GRIM-12-transfected cells exhibited a growth rate
of only 60% compared to cells transfected with vec-
tor alone. Finally, we determined whether GRIM-12-
transfected cells were more sensitive to IFN/Tam-in-
duced cell death. IFN/Tam caused three times more
cell death in GRIM-12-expressing cells compared to
those expressing vector alone (Fig. 11A). Cell death
Fig. 10. E¡ect of 10 WM AZ on IFN/Tam (IT) induced cell
death. MCF-7 cells were incubated with indicated agents and
growth was measured after 6 days. Note the cell death induc-
tion by IT and its inhibition by AZ.
Fig. 11. (Upper panel) Increased TR expression in MCF-7 cells
results in enhanced sensitivity to IFN/Tam. Pools of stable
transfectants expressing vector alone (pCXN2) or sense GRIM-
12 were treated with IFN-L (500 U/ml) and Tam (0.5 WM) for
1 to 5 days and stained with Trypan blue. (Lower panel) Pools
of stable transfectants, similarly treated, were stained with an-
nexin-V-FITC and subject to £ow cytometry. Percentage of
cells positive for annexin-V are represented as mean þ S.E.M. of
three samples.
BBAMCR 14611 4-4-00
D.J. Lindner et al. / Biochimica et Biophysica Acta 1496 (2000) 196^206 203
appeared to peak after 4 days of drug treatment.
Indeed, death occurred by apoptosis, as measured
by annexin-V staining (Fig. 11B).
4. Discussion
In this study we have shown that combination of
IFN-K/L and Tam causes cell death (Fig. 1).
Although, no internucleosomal genomic fragmenta-
tion was observed in MCF-7 cells, these cells bound
annexin-V, an early event consistent with apoptotic
death. One defect that could account for this behav-
ior is the deletion of the caspase 3 gene in MCF-7
cells. That said, in a number of conditions, internu-
cleosomal DNA fragmentation is dispensable for
programmed cell death [42^46]. Lack of classical in-
ternucleosomal fragmentation in MCF-7 cells could
also be due to the lack of functional caspase-3. NIH-
OVCAR-3 cells seem to undergo classic apoptotic
death, perhaps due to the presence of active casp-
ase-3. The fact that IFN-K/L but not IFN-Q was
capable of inducing cell death in association with
Tam indicates that di¡erent intracellular factors par-
ticipate in the growth suppressive actions of various
IFNs. Consequently their antitumor spectrum is dis-
tinct. The IFN-stimulated growth suppressive en-
zymes, PKR and RNaseL, [11,12] do not seem to
be necessary for death to occur since neither their
levels nor their activities have changed during IFN/
Tam treatment. A similar pattern of cell death was
noted with the IFN/RA combination. Therefore,
IFN-L/Tam-induced cell death may di¡er from the
known apoptotic pathways and may utilize unde-
¢ned gene products. Application of genetic tech-
niques indicated that GRIM-12 (TR) mediates
IFN/RA induced cell death. Since both IFN/RA
and IFN/Tam exert similar death program in tumor
cells, we examined whether GRIM-12 also partici-
pated in IFN/Tam induced death. Indeed, antisense
expression of GRIM-12 protected cells from IFN/
Tam-induced death (Fig. 6).
The observation that antisense mRNA and domi-
nant negative inhibitors of GRIM-12 confer death
resistance suggests that suppression of the physiolog-
ical levels of the enzyme or interference with its func-
tion is su⁄cient to prevent cell death (Fig. 9). Indeed,
cells that resist IFN/Tam induced cell death have the
lowest TR activity. Over expression of NBD and ID
signi¢cantly inhibited death, with the latter confer-
ring most protection against IFN/Tam-induced
death. It is possible that NBD may interfere with
optimal activities of other death-associated redox en-
zymes by sequestering NADPH, including TR. Since
the ID is required for generating a functional en-
zyme, it may interfere with the dimerization of en-
zyme polypeptide, although the exact in vivo confor-
mation of the mutant ID molecule is uncertain.
Therefore, it may strongly inhibit enzyme activity
and cell death. The di¡erential sensitivity of trans-
fectants to cell death was not due to a di¡erence in
the levels of endogenous TR and mutant domains of
GRIM-12 (data not shown). Since we do not have a
speci¢c antibody that detects all these mutants, it has
not been possible to demonstrate the expression of
the mutant proteins. However, enzyme assays re-
vealed that overexpression of ID strongly interfered
with enzymatic activity. A direct role for TR in IFN/
Tam mediated cell death was supported by several
observations. (1) Cell death was inhibited by the mu-
tants or antisense. (2) GRIM-12-expressing cells are
more sensitive to the death e¡ects of IFN/Tam com-
pared to those expressing vector alone. (3) A chem-
ical inhibitor (AZ) of TR suppressed IFN/Tam-in-
duced cell death (Fig. 10).
TR and its substrate Trx are well conserved in
evolution, perhaps because they are crucial regula-
tors of the intracellular redox state. Based on the
ability of exogenous and transfected Trx to stimulate
cell growth, it has been proposed that the TR:Trx
system acts as a cell growth promoter [47,48]. Our
results and those of others [49,50] argue that TR and
Trx are growth inhibitory molecules. How do we
reconcile these con£icting observations? A primary
di¡erence between our studies and others is the pres-
ence of selection pressure exerted by stress inducing
or cytotoxic agents. Thus, in the absence of cytotoxic
agents, TR:Trx supports normal cell growth proc-
esses. However, in the presence of inhibitory pressure
(e.g. IFNs or IFN/Tam), the TR:Trx system may
activate factors that cause cell death. Unlike studies
that emphasize the pro-growth activity of TR, our
studies and those of others [49] lower the physiolog-
ical TR or Trx levels to provide a growth advantage.
Alternatively, TR might employ di¡erent substrates
for activating cell death and for promoting growth.
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Indeed, mammalian TR also reduces selenite, allox-
an, vitamin K and 5,5P-dithiobis (2-nitrobenzoic
acid) in vitro [38,51,52]. Based on these observations
we suggest that TR:Trx act as a dual switch in
growth control [53]. In an analogous manner, de-
pending on the physiologic status of the cell, the
protooncogene myc can act as a growth promoter,
or as a mediator of cell death [54,55].
Although the downstream molecular events that
mediate TR:Trx-induced cell death are still unclear,
genetic evidence provided by others and us suggest
the novel death regulatory roles of oxidoreductases.
For example, human p53 induced gene expression
and growth inhibition are defective in yeast mutant
that lack TR [56]. Furthermore redox factor-1 (ref-1)
which stimulates p53 function, is a downstream sub-
strate of TR:Trx system [57]. Deletion of Trx genes
in yeast leads to an increase in the mitotic cycle and
DNA replication rates [58]. TR also inhibited gene
induction from MluI cell cycle (MCB) boxes present
in the promoters of genes that regulate yeast cell
growth [59]. More importantly, some p53-induced
cell death genes are oxido-reductases [60]. The fact
that the IFN/Tam combination continued to inhibit
cell growth despite TR inhibition suggests the pres-
ence of other inducible, TR-independent cell growth
suppressive pathways. Since overexpression of
GRIM-12 (TR) alone does not kill the majority of
transfected cells, ligand-induced post translational
modi¢cations and expression of other IFN/Tam-in-
duced death regulators are necessary for death to
occur, in addition to increased TR levels.
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